Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Company”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, recently announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of AUD.

All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.